Skip to search formSkip to main contentSkip to account menu

Denintuzumab Mafodotin

Known as: DENITUZUMAB MAFODOTIN, Immunoglobulin G1-kappa Auristatin F Conjugate, Anti-(homosapiens CD19 (B Lymphocyte Surface Antigen B4, leu-12)), Humanized Monoclonal Antibody 
An immunoconjugate consisting of an anti-CD19 monoclonal antibody conjugated to the auristatin derivative monomethyl auristatin F (MMAF), with… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Denintuzumab mafodotin (SGN‐CD19A) is a CD19‐targeting antibody‐drug conjugate, comprising a monoclonal antibody conjugated to… 
2019
2019
Multiple myeloma (MM) is a plasma cell malignancy characterized by clonal proliferation of plasma cells within the bone marrow. B… 
2019
2019
Abstract Background In BMA117159, GSK2857916, a humanised (IgG1), afucosylated, anti-BCMA monoclonal antibody conjugated to… 
2016
2016
Denintuzumab Mafodotin (SGN-CD19A) is an antibody-drug conjugate (ADC) composed of an anti-CD19 antibody attached to a synthetic… 
1987
1987
Human monocytes actively replicate dengue virus. To dissect the primary immune responses to dengue virus-infected monocytes (DV… 
1987
1987
Patients with myeloma have a depressed capacity to respond to antigenic challenge. Studies in this laboratory have previously… 
1986
1986
A limiting dilution procedure using lymphocytes isolated by FACS is described to assess the role of individual T cell subsets for…